Clinical Trials Logo

Retinal Detachment clinical trials

View clinical trials related to Retinal Detachment.

Filter by:

NCT ID: NCT05588037 Recruiting - Cataract Clinical Trials

Combined Vitrectomy and Femtosecond Laser-assisted Cataract Surgery

Start date: January 1, 2017
Phase: N/A
Study type: Interventional

Based on the progress of cataract surgery, intraocular lens development, vitreoretinal surgery and anesthesia technology in recent years, the purpose of this study is to develop a new type of more accurate and minimally invasive combined surgery for cataract and fundus diseases, and to evaluate the advantages and value of the surgery as well as related complications, so as to minimize the surgical trauma and obtain faster visual function recovery and better patient comfort. To provide new solutions for the growing demand of eye health care.

NCT ID: NCT05583253 Recruiting - Refractive Errors Clinical Trials

Visual Outcome of Vitrectomy After Refractive Surgery

Start date: October 13, 2022
Phase: N/A
Study type: Interventional

Results of retinal detachment surgery may be affected in cases with history of previous intraocular surgery.

NCT ID: NCT05566626 Enrolling by invitation - Clinical trials for Macular Degeneration

Retinal Oxygenation Estimation Trial With Mantis Photonics Hyperspectral Camera

Start date: October 2022
Phase: N/A
Study type: Interventional

An explorative study of the Mantis Photonics hyperspectral camera for retinal imaging and estimation of retinal oxygenation. Primary objective: To evaluate the performance of the hyperspectral camera for non-invasive retinal examination in order to improve the diagnosis of diseases affecting the retina or central nervous system. Secondary objective: To investigate the possibilities of the use of a hyperspectral camera for non-invasive retinal examination.

NCT ID: NCT05561569 Recruiting - Retinal Detachment Clinical Trials

Air Versus Gas Tamponade in Primary Retinal Detachment

Start date: September 26, 2022
Phase: N/A
Study type: Interventional

Management of primary retinal detachment due to upper retinal break is one of controversial situation that may face ophthalmologists in vitreoretinal subspecialty.

NCT ID: NCT05543018 Recruiting - Glaucoma Clinical Trials

Effect of Intraocular Tamponade on Visual Perception

Start date: September 12, 2022
Phase: N/A
Study type: Interventional

Intraocular tamponade used in vitrectomy operations may affects retinal function in various mechanisms.

NCT ID: NCT05538156 Not yet recruiting - Retinal Detachment Clinical Trials

Internal Limiting Membrane Peeling in Retinal Detachment Surgery

IMPURITY
Start date: September 2022
Phase: N/A
Study type: Interventional

Despite advances in surgical techniques over the recent decades, proliferative vitreoretinopathy (PVR) remains the main obstacle to successful rhegmatogenous retinal detachment (RRD) repair, accounting for nearly 75% of all primary surgical failures. It is characterized by the growth and contraction of cellular membranes within the vitreous cavity and on both surfaces of the detached retina as well as intraretinal fibrosis. The Retina Society classification, modified in 1991 and currently the most widely used, divided PVR into three grades. Grade A is limited to the presence of vitreous haze and pigment clumps. Grade B includes rolled or irregular edges of tear and/or inner retinal surface wrinkling with possible retinal stiffness and vessel tortuosity. Grade C is defined as the presence of full-thickness fixed retinal folds and is further subdivided based on the number of hours involved and the location. Recently, Foveau et al., in a retrospective comparative case series, have demonstrated that performing internal limiting membrane (ILM) peeling during RRD surgery may increase the anatomical success rate for this indication. The aim of this multi-center, prospective, randomized controlled clinical trial study is to evaluate the effectiveness of ILM peeling on surgical outcomes in patients with primary macula-off RRD complicated by grade B PVR.

NCT ID: NCT05523869 Recruiting - Clinical trials for Proliferative Vitreoretinopathy in Rhegmatogenous Retinal Detachment

Intravitreal Topotecan in the Repair of Rhegmatogenous Retinal Detachment With Proliferative Vitreoretinopathy

TOPO-RD
Start date: February 23, 2023
Phase: Phase 2
Study type: Interventional

Intravitreal topotecan has anti-inflammatory, anti-proliferative and anti-fibrotic activity that we hypothesize may exhibit high efficacy for the treatment of proliferative vitreoretinopathy (PVR) in patients with rhegmatogenous retinal detachment (RRD). A high efficacy for intravitreal topotecan has been exhibited in cell cultures of PVR. At the same time, intravitreal topotecan has been routinely used in the treatment of vitreous seeds from retinoblastoma. At doses of 5-30 micrograms per injection, no adverse events have been reported with the use of intravitreal topotecan. Therefore, the current prospective matched phase II trial aims to investigate the efficacy and safety of intravitreal topotecan for severe PVR in patients with RRD.

NCT ID: NCT05514925 Recruiting - Clinical trials for Proliferative Diabetic Retinopathy

Cryoapplication Versus Anti-VEGF Before Diabetic Vitrectomy

Start date: November 21, 2017
Phase: Phase 4
Study type: Interventional

Pars-plana vitrectomy (PPV) is the cornerstone of surgical treatment for eyes with complicated proliferative diabetic retinopathy. Anti-VEGF intravitreal injection before PPV has shown a good effect on surgical outcomes. However, many patients present with co-morbidities that contraindicate the usage of anti-VEGF in the pre-operative period. Thus, cryoapplication, an old therapeutic tool for proliferative diabetic retinopathy may be a good alternative. The investigators present herein a comparative study between peripheral retinal cryoapplication and anti-VEGF before vitrectomy for complicated proliferative diabetic retinopathy.

NCT ID: NCT05414747 Suspended - Retinal Detachment Clinical Trials

Clinical Investigation of the Safety and Effectiveness of the ABV-1701 Ocular Endotamponade (OE)

Start date: April 15, 2023
Phase: N/A
Study type: Interventional

A Prospective Multi-Site Open Label Randomized Controlled Clinical Investigation of the Safety and Effectiveness of the ABV-1701 Ocular Endotamponade (OE)

NCT ID: NCT05377606 Completed - Clinical trials for Rhegmatogenous Retinal Detachment

Primary Vitrectomy With Silicone Oil or SF6 for Rhegmatogenous Retinal Detachment

Start date: December 23, 2021
Phase: N/A
Study type: Interventional

Rhegmatogenous retinal detachment (RRD) is the separation of the neurosensory retina from the retinal pigment epithelium caused by the presence of a break that leads to the passage of fluid from the vitreous cavity into the potential subretinal space. It is a sight threatening disease, affecting largely people 50 years or older, with an annual incidence varying between 6.3 and 17.9 people per 100,000 population, and is unfortunately increasing. Although other surgical options do exist for the repair of primary RRD, pars plana vitrectomy (PPV) has clear advantages and is certainly effective in the treatment of these patients. Several agents are used for intraocular tamponade following PPV for RRD. These agents are either silicone oil (SO) or gases like air, perfluoropropane (C3F8), sulfur hexafluoride (SF6), or perfluoroethane (C2F6). In addition to the complications uniquely peculiar to using SO, research has found out that a reduction in retinal sensitivity on microperimetry was greater in SO tamponade in comparison with gas, as well as poorer visual outcome, microvasculature damage and affection of retinal layers including ganglion cell complex (GCC) in the SO group. Even though many studies were done to compare between SO and intraocular gas tamponades with respect to many aspects, only one study compared the effects SO had on macular vasculature and anatomy in comparison with air and no study at all to date has compared the SO to SF6 gas in terms of retinal vascular changes, correlating them to thinning of GCC and macular sensitivity, which is precisely the main aim of the current study.